Phage Futures Europe 2021

Translating phage-based applications into clinically and commercially viable therapeutics.

VIEW THE 2021 AGENDA
Brussels, Belgium
23-24 November, 2021

“Great overview of the field, key players were present, strong opening with focus on patient to orient the audience what matters.”

Dirk Gevers, Global Head, Janssen Human Microbiome Institute, J&J

As a preview ahead of Phage Futures Europe, take a look at highlights from the 2021 Phage Futures USA Congress that took place online in February.

Why Attend

Join us for the return of Phage Futures Europe, this November 2021 in Brussels, as we continue all-important discussions on translating new phage-based applications into clinical studies and beyond. Network and learn from multinational pharma, emerging biotechs, leading academics, investment representatives and regulatory bodies to discover how you can be at the forefront of the developing phage therapy market.

Introducing face-to-face interactions once again, Phage Futures Europe will help you maximise networking and commercial development with key industry players such as GSK, BiomX, Contrafect and more. This year, we discuss the viability of phage derived lysines in therapy, assess the therapeutic application of natural phages vs engineered phages and explore the clinical data surrounding the magisterial and compassionate use of phages in Europe. 

Bacteriophages have seen continued investment and have adapted to global challenges, introducing commercial and marketable prospects for phage application. Phage Futures Europe explores the commercial applications of phages in poultry, aquaculture, biocontrol and skin microbiome, providing insights into the global design of phage products and acquiring pharmaceutical partnerships.

TALK TO OUR SPEAKERS ABOUT...

1. How to design a successful phage clinical trial

2. How to manipulate the microbiome with phage therapy to treat chronic diseases

3. The implications and safety requirements of administering phage therapy to patients

4. What indications are suitable for phage therapy within Europe?

5. How to obtain broad phage host range and maintain synergy within a fixed cocktail

6. Applications of phage related products as an alternative strategy to access the market 

7. How magistral preparative supports the personalised medicine method

8. The route to appropriate clinical data: through innovative trial design

9. How to alleviate future multi-drug resistance through phage evolution research

10. What are the commercial pathways for phage therapies?

Advisory Board

Author:

Dr Gina Suh

Infectious Disease Specialist
Mayo Clinic

Author:

Dr Todd Black

Executive Director of Infectious Diseases/Vaccines
Merck

Author:

Jessica Sacher

Co-Founder
Phage Directory

Author:

Sandra Giannini

Director
GSK

Author:

Ruby Lin

Deputy Director of Phage, Australia
The Westmead Institute

Who Will Be There

5%
Regulatory / Government
5%
Service Providers
15%
Physicians / Clinicians
20%
Biotechs
25%
Multinationals
30%
Academics

Regulatory / Government

Service Providers

Physicians / Clinicians

Biotechs

Multinationals

Academics

Past attendees

TESTIMONIALS

SPEAKERS

 

Dr Peter Beyer

Unit Head, Antimicrobial Resistance Division
WHO

Peter Beyer, a trained lawyer, is a Senior Advisor with the World Health Organization (WHO) in Geneva where he leads a team working on global initiatives on antimicrobial resistance. He focuses on developing global instruments to combat antimicrobial resistance and to foster the development of new antimicrobial treatments.

Dr Peter Beyer

Unit Head, Antimicrobial Resistance Division
WHO

Dr Peter Beyer

Unit Head, Antimicrobial Resistance Division
WHO

Peter Beyer, a trained lawyer, is a Senior Advisor with the World Health Organization (WHO) in Geneva where he leads a team working on global initiatives on antimicrobial resistance. He focuses on developing global instruments to combat antimicrobial resistance and to foster the development of new antimicrobial treatments. Peter was instrumental in setting up the Global Antibiotic R&D Partnership (GARDP), a foundation that is developing new antibacterial treatments as well as the trilateral collaboration among the World Intellectual Property Organization (WIPO), the World Trade Organization (WTO) and WHO. Previously, Peter Beyer was a Legal Advisor to the Swiss Federal Institute of Intellectual Property in Berne. He negotiated bilateral free trade agreements for the European Free Trade Association (EFTA) and was responsible for the bilateral dialogue between Switzerland and China on intellectual property. Prior to joining the Swiss civil service, Peter Beyer worked with the Ecologic Institute in Berlin on environmental law and policy.

 

Dr Todd Black

Executive Director of Infectious Diseases/Vaccines
Merck

Dr Todd Black

Executive Director of Infectious Diseases/Vaccines
Merck

Dr Todd Black

Executive Director of Infectious Diseases/Vaccines
Merck
 

Dr Frenk Smrekar

CEO & Co-Founder
JAFRAL Ltd

Dr Frenk Smrekar

CEO & Co-Founder
JAFRAL Ltd

Dr Frenk Smrekar

CEO & Co-Founder
JAFRAL Ltd
 

Dr Gina Suh

Infectious Disease Specialist
Mayo Clinic

Dr Gina Suh

Infectious Disease Specialist
Mayo Clinic

Dr Gina Suh

Infectious Disease Specialist
Mayo Clinic
 

Sarah Dejebara

Doctor of Medicine
Queen Astrid Military Hospital

Sarah Dejebara

Doctor of Medicine
Queen Astrid Military Hospital

Sarah Dejebara

Doctor of Medicine
Queen Astrid Military Hospital
 

Dr. Jean-Paul Pirnay

Head of the Laboratory for Molecular and Cellular Technology
Queen Astrid Military Hospital

Dr. Jean-Paul Pirnay

Head of the Laboratory for Molecular and Cellular Technology
Queen Astrid Military Hospital

Dr. Jean-Paul Pirnay

Head of the Laboratory for Molecular and Cellular Technology
Queen Astrid Military Hospital
 

Dr Shawna McCallin

Clinical Coordinator
Balgirst University Hospital

Dr Shawna McCallin

Clinical Coordinator
Balgirst University Hospital

Dr Shawna McCallin

Clinical Coordinator
Balgirst University Hospital
 

Dr Steven Theriault

CEO & CSO
Cytophage Technologies Inc.

Dr. Steven Theriault is a passionate scientist with 20 years of research and entrepreneurial experience in generating biological solutions for biological problems. He founded Cytophage Technologies Inc., a company that uses natural, modified and synthetic bacteriophages to create a diversity of products that combat bacterial infections affecting human health, animal health and food security. Dr.

Dr Steven Theriault

CEO & CSO
Cytophage Technologies Inc.

Dr Steven Theriault

CEO & CSO
Cytophage Technologies Inc.

Dr. Steven Theriault is a passionate scientist with 20 years of research and entrepreneurial experience in generating biological solutions for biological problems. He founded Cytophage Technologies Inc., a company that uses natural, modified and synthetic bacteriophages to create a diversity of products that combat bacterial infections affecting human health, animal health and food security. Dr. Theriault’s goal is to enable bacteriophages to become mainstream for treating human and animal bacterial infections, thereby averting the WHO’s predicted AMR crisis and avoiding needless suffering.

 

Natalie Ma

Co-Founder
Felix Biotechnology

Natalie Ma

Co-Founder
Felix Biotechnology

Natalie Ma

Co-Founder
Felix Biotechnology
 

Dr David Harper

CEO and CSO
Evolution Biotechnologies

My day job is as the CEO of Evolution Biotechnologies, moving environmentally friendly biological controls into the biomedical sector, based on the success of such agents in agriculture. This is based around low cost approaches minimising investor dilution while moving towards large potential markets.

Dr David Harper

CEO and CSO
Evolution Biotechnologies

Dr David Harper

CEO and CSO
Evolution Biotechnologies

My day job is as the CEO of Evolution Biotechnologies, moving environmentally friendly biological controls into the biomedical sector, based on the success of such agents in agriculture. This is based around low cost approaches minimising investor dilution while moving towards large potential markets.

Targets include the house dust mite, the main cause of asthma, where our novel approach underlies broad patent protection, and antibiotic resistant bacterial infections where individual veterinary treatments are already being undertaken. The company is building on its unique skillset in these key areas.

 

Dr. Cindy Fevre PhD

Director of R&D
Pherecydes Pharma

Dr. Cindy Fevre PhD

Director of R&D
Pherecydes Pharma

Dr. Cindy Fevre PhD

Director of R&D
Pherecydes Pharma
 

Dr. Lorenzo Corsini

CEO, Research & Development
PhagoMed

Dr. Lorenzo Corsini

CEO, Research & Development
PhagoMed

Dr. Lorenzo Corsini

CEO, Research & Development
PhagoMed
 

Chandra Ghose

CEO
Bioharmony Therapeutics

Chandra Ghose

CEO
Bioharmony Therapeutics

Chandra Ghose

CEO
Bioharmony Therapeutics
 

Tristan Ferry MD, PhD

Professor of Medicine
University of Lyon

Tristan Ferry MD, PhD

Professor of Medicine
University of Lyon

Tristan Ferry MD, PhD

Professor of Medicine
University of Lyon
 

Tobi Nagel

Founder
Phages for Global Health

Tobi Nagel

Founder
Phages for Global Health

Tobi Nagel

Founder
Phages for Global Health
 

Dr Danish Malik

Reader in Industrial Biotechnology
Loughborough University

Dr Danish Malik

Reader in Industrial Biotechnology
Loughborough University

Dr Danish Malik

Reader in Industrial Biotechnology
Loughborough University
 

Dr. Bob Blasdel

Research Director
Vesale Pharma

I work as the Research Director for Vésale Bioscience where I contribute my ten years’ experience in the phage therapy field as well as my expertise in the biology of phages on a microbiological, molecular, structural, multi‘-omics’, and regulatory level. We work on progressing the personalized model of phage therapy, developing and manufacturing phages as APIs for magistral preparations according to the European model of phage therapy.

Dr. Bob Blasdel

Research Director
Vesale Pharma

Dr. Bob Blasdel

Research Director
Vesale Pharma

I work as the Research Director for Vésale Bioscience where I contribute my ten years’ experience in the phage therapy field as well as my expertise in the biology of phages on a microbiological, molecular, structural, multi‘-omics’, and regulatory level. We work on progressing the personalized model of phage therapy, developing and manufacturing phages as APIs for magistral preparations according to the European model of phage therapy.

I spend a lot of time thinking about what I'm going to eat next, why cows tend to orient themselves on a north/south axis, whether viruses are alive or non-living (or undead!), what it could have really been like to have lived under the laws of Solon, structure/function arguments in biology, and the value that I like to pretend the Oxford comma has for ameliorating run-on sentences.

 

Heather Fairhead

CEO
Phico Theraputics

Heather Fairhead

CEO
Phico Theraputics

Heather Fairhead

CEO
Phico Theraputics
 

Matthew Tebeau

Chief Operating Officer
Proteon Pharmaceuticals SA

Matthew Tebeau

Chief Operating Officer
Proteon Pharmaceuticals SA

Matthew Tebeau

Chief Operating Officer
Proteon Pharmaceuticals SA
 

Dr Dave Ousterout

CSO & Co-Founder
Locus Bisociences

Dave Ousterout is a co-founder and Chief Scientific Officer for Locus Biosciences. Dave holds a PhD from Duke University where he developed novel gene editing approaches for correcting mutations that cause Duchenne muscular dystrophy. His expertise is in protein engineering and early stage applications of new technologies to treat human diseases. At Locus, Dave is responsible for development of Locus’s crPhage platform and early stage product development. Prior to Locus, Dave was a consultant at McKinsey & Company.

Dr Dave Ousterout

CSO & Co-Founder
Locus Bisociences

Dr Dave Ousterout

CSO & Co-Founder
Locus Bisociences

Dave Ousterout is a co-founder and Chief Scientific Officer for Locus Biosciences. Dave holds a PhD from Duke University where he developed novel gene editing approaches for correcting mutations that cause Duchenne muscular dystrophy. His expertise is in protein engineering and early stage applications of new technologies to treat human diseases. At Locus, Dave is responsible for development of Locus’s crPhage platform and early stage product development. Prior to Locus, Dave was a consultant at McKinsey & Company.

 

Cara Casino

M.D. Chief Medical Officer
Contrafect

Cara Casino

M.D. Chief Medical Officer
Contrafect

Cara Casino

M.D. Chief Medical Officer
Contrafect
 

Dr Adam Ostrowski

Technical Applications Specialist
Cellexus

Adam is a molecular microbiologist and an applications specialist at Cellexus International Ltd, where he helps customers find the optimal combination of bioreactor solutions offered by Cellexus and achieve the best possible results using our technology. Adam also helps develop new applications and technical solutions for our airlift-mixed single-use bioreactor range and delivers custom requests and improvements requested by our customers.

Dr Adam Ostrowski

Technical Applications Specialist
Cellexus

Dr Adam Ostrowski

Technical Applications Specialist
Cellexus

Adam is a molecular microbiologist and an applications specialist at Cellexus International Ltd, where he helps customers find the optimal combination of bioreactor solutions offered by Cellexus and achieve the best possible results using our technology. Adam also helps develop new applications and technical solutions for our airlift-mixed single-use bioreactor range and delivers custom requests and improvements requested by our customers. Before joining Cellexus, Adam worked in bacteriophage treatment development for plant crop protection and during his academic career has studied Type VI Secretion system and functional proteins in bacterial communities.

 

Olivia McAuliffe

Research Officer
Teagasc Food Research Centre

Olivia McAuliffe

Research Officer
Teagasc Food Research Centre

Olivia McAuliffe

Research Officer
Teagasc Food Research Centre
 

Dr. Edith Hessel

CSO
Eligo Bioscience

Dr. Edith Hessel

CSO
Eligo Bioscience

Dr. Edith Hessel

CSO
Eligo Bioscience
 

Dr Panos G. Kalatzis

Regional Aqua Manager
Adisseo

Dr Panos G. Kalatzis

Regional Aqua Manager
Adisseo

Dr Panos G. Kalatzis

Regional Aqua Manager
Adisseo
 

Dr Cara Fiore

Senior Regulatory Reviewer, Microbiologist
FDA

Dr Cara Fiore

Senior Regulatory Reviewer, Microbiologist
FDA

Dr Cara Fiore

Senior Regulatory Reviewer, Microbiologist
FDA
 

Viviana Clavijo

CEO
SciPhage

Viviana Clavijo

CEO
SciPhage

Viviana Clavijo

CEO
SciPhage
 

Sofia Corte-Real

Scientific Advisor
Technophage

Sofia Corte-Real

Scientific Advisor
Technophage

Sofia Corte-Real

Scientific Advisor
Technophage
 

Ruby Lin

Deputy Director of Phage, Australia
The Westmead Institute

Ruby Lin

Deputy Director of Phage, Australia
The Westmead Institute

Ruby Lin

Deputy Director of Phage, Australia
The Westmead Institute

AGENDA

Download your copy of the Phage Futures Europe 2021 agenda! 

What you can expect from the Europe 2021 congress:

  • 200+ participants from academic, industry, biotech and regulatory bodies onsite
  • European and global phage thought leaders on the speaking agenda and ready to answer your big questions
  • 2 days of furthering phage therapy

Key speakers include:

New content for 2021: 

"First conference really focused on moving phage therapy and phage-related technologies forward. A great combination of regulatory, commercial, and scientific presentations." – Shawna McCallin, Phage Forward

Download 2021 Europe Agenda

Headline Partner

Event Partner

Lead Media Partner

Media Partners

Become a Partner

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

POSTER SESSION

Looking to showcase your recent work to the phage therapy community?

Our dedicated poster session is the perfect way to get your research noticed. Ideal for PhD students or Post-Doctoral researchers.

In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area. 

Poster abstract submission deadline: 15th October 2021. Posters should be sized A0 (841mm x 1189mm) in portrait orientation.

Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!

For more information please contact [email protected]

APPLY HERE



Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Preparing registration...

Returning Safely Measures

Whether sponsors, speakers or attendees, our customers attend Kisaco Research events to connect, learn and innovate to know more and do business. It is our commitment that as we return to in-person events, they can do this effectively, safely and with confidence.

All in-person Kisaco Research events will prioritize the health and safety of colleagues and customers and, in the first instance, will be run in accordance with official government and local authority guidance, as well as any venue or location-specific regulations.

Kisaco Research is committed to following the Association of Event Organisers All Secure Standard, which has been approved by by UK Government.

Download the Kisaco Research Returning Safely Measures 

Venue

Pullman Brussels Centre Midi, Place Victor Horta 1, 1060 Bruxelles, Belgium

A stay at Pullman Brussels Centre Midi places you in the heart of Brussels, walking distance from Midi Market and Cantillon Brewery. This 4-star hotel is within close proximity of Law Courts of Brussels and Manneken Pis Statue.

Make yourself at home in one of the 237 air-conditioned rooms featuring refrigerators and MP3 docking stations. Wired and wireless Internet access is complimentary, and flat-screen televisions with digital programming provide entertainment. Private bathrooms have deep soaking bathtubs and complimentary toiletries. Conveniences include phones, as well as safes and desks.

Get 10% off your room rate, please note that in order to achieve the 10% discount you will need to become an Accor Member.

Click here to reserve your room. 

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us